High-Risk Hodgkin Lymphoma: Staging, Biologic Markers, and Management With Brentuximab VedotinChapter 1
Patrick J. Stiff, MD, of the Cardinal Bernardin Cancer Center in Maywood, Illinois, provides an overview of the staging, biologic markers, and other factors tied to risk for recurrence in patients with Hodgkin disease, and highlights the long-term remission achieved for many patients who received brentuximab vedotin.
Jeffrey Schriber, MD, FRCP, of the Cancer Transplant Institute of Arizona Oncology in Scottsdale, Arizona, underscores the role of brentuximab vedotin, in combination with autologous hematopoietic stem cell transplantation, in preventing the recurrence of Hodgkin lymphoma, and obviating the need for allogeneic transplantation.
Steven M. Ansell, MD, PhD, of the Mayo Clinic in Rochester, Minnesota, discusses the role of brentuximab vedotin in multiple settings for patients with classical Hodgkin lymphoma—in combination with chemotherapy as first- and second-line therapy, as consolidation for Hodgkin patients at risk for recurrence following an autologous hematopoietic stem cell transplant, and as treatment post-autologous transplant for relapsed/refractory patients.
John W. Sweetenham, MD, Senior Director of Clinical Affairs at the Huntsman Cancer Institute, University of Utah in Salt Lake City, Utah, analyses the results of the pivotal AETHERA trial of brentuximab vedotin for patients with Hodgkin lymphoma who are at risk of relapse following an autologous stem cell transplant.